Stockreport

Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer

ENDOCYTE  (ECYT) 
Last endocyte earnings: 11/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.endocyte.com/investor-relations
PDF - Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Bil [Read more]